The latest information regarding the BioCanRx research network and biotherapeutic research.
View this email in your browser
Moving from the lab to the clinic
by Heather Blumenthal

It’s one thing to be known among your friends for your famous boeuf bourguignon recipe. It’s another thing entirely to open your own restaurant based on that recipe. All of a sudden you need to deal with things like quality of ingredients, scaling up that favourite recipe to serve multiple times a night, and making sure that each serving is of consistently high standards and won’t accidently make a customer sick.

It’s much the same thing with T cells, a type of white blood cell that’s particularly good at attacking tumors. But taking them out of the lab and into the clinic takes a lot of work – work that the BC Cancer Agency’s Dr. Brad Nelson is focused on right now.
BioCanRx funding opportunities:
BioCanRx Rolling Open-Call
   Stay tuned for deadline details

Other funding opportunities currently available:

Ontario Research Fund - Research Excellence (ORF-RE) program
The Ontario Ministry of Research, Innovation and Science (MRIS)
   Deadline for NOIs: May 2, 2017 
   Full application deadline: September 25, 2017
Training Programs: 

HQP Travel Awards – travel support to attend external training and educational events identified by HQP (i.e. conferences, workshops, etc.)
  Funding: Up to $1,000 CAD
  Deadline: Various throughout the year, closest one: June 9, 2017

Lab Exchanges – travel support for knowledge and technology exchange between research labs or industry

  Funding: Up to $3,000
  Deadline: Various throughout the year


Media Relations: How to get your story into the press
  March 23, 2017 from 1:00 - 2:00 PM EST
  Part of the SMRTS Seminars Program for professional skills development, this seminar will     be hosted by the Ontario Institute for Regenerative Medicine. 

You can find information about training, education and career opportunities at the BioCanRx Training website.
Speakers Set for 2017 Summit for Cancer Immunotherapy

The keynote speakers are set for BioCanRx’s 2017 Summit for Cancer Immunotherapy (Summit4CI) this June 25 – 28, in Gatineau, Quebec. We are pleased to have Robert Andtbacka (Huntsman Cancer Institute) and Stanley Riddell (Fred Hutchinson Cancer Research Center) deliver the opening keynote presentations on the evening of Sunday, June 25 and Dr. Jeffrey Hoch (UC Davis) deliver the closing keynote on Wednesday, June 28. 
Summit4CI will bring together more than 250 leading scientists, clinicians, students and economists with representatives from industry, patient groups, charities and government. The Summit will explore the latest progress in cancer biotherapeutics from scientific, clinical, industry and patient perspectives through internationally recognized speakers, scientific presentations, poster sessions, panel discussions and networking opportunities. Here are some of the plenary session topics scheduled for Summit4CI:
  • The Microbiome
  • Novel Preclinical Models & In Vitro Screening Platforms
  • Antibodies & Antibody-like Molecules
  • Innate Immunity
  • Oncolytic Viruses & Viral Vaccines
  • Adoptive Cell Therapy: Beyond Melanoma
We hope to see you at Summit4CI being held this year in the national capital region to celebrate Canada's 150th birthday! Check out the Summit website for full program details, additional distinguished speakers, registration and sponsorship information:
cancer summit, cancer conference
Summit for Cancer Immunotherapy 2017 

Early Bird Registration
Summit registration is open - register before April 19, 2017, for the Early Bird Discount
Final Registration Deadline: May 17, 2017

HQP Career Development Day
Check out the agenda for this HQP training workshop

Sunday, June 25, 2017

Travel Award Competition - ClosedPrimary authors will notified of the competition results by Friday, March 31, 2017

Abstract Submissions
Final deadline: May 3, 2017

Other upcoming events:

Innovative approaches to optimal cancer care in Canada
CPAC | April 7-8, 2017

Vaccine Innovation Conference
BIOTECanada | May 10, 2017

Science Odyssey - Ten days of discovery and innovation
May 12 to 21, 2017

ARCC Conference 2017
May 25 to 26, 2017 | Toronto, ON

CDRD Symposium: Novel Strategies in Cancer Immunotherapy
May 26, 2017 | Vancouver, BC
Dr. John Bell, BioCanRx's Scientific Director and Senior Scientist at The Ottawa Hospital spoke on oncolytic viruses to promote anticancer activity at the #CellCANforum
Working with Patients to Inform Early-phase Cancer Clinical Trial Design
March 8, 2017 - This successful workshop is in thanks of the partnerships between BioCanRx, CellCAN and the Ottawa Hospital Research Institute. The workshop received positive feedback from participants who were in agreement that the learning objectives had been met. This learning opportunity highlighted BioCanRx’s first push to incorporating the patient voice into its research program. Attendees included BioCanRx highly qualified personnel, Cancer Stakeholder Alliance members, and other patient-focused organizations. Presenting were Network investigators Manoj Lalu and Justin Presseau, along with patient Anne Lyddiatt and SPOR Program Facilitator Zarah Monfaredi, covering topics such as what patient-oriented research is, how it is used to inform and impact clinical trials currently, and how BioCanRx intends to conduct patient-oriented research to inform cancer clinical trial design of the first made-in-Canada CAR-T therapy.
Stay tuned for more discussions in patient-oriented research at our Summit for Cancer Immunotherapy in June 2017!
Network members: Feature your research here by sending us a link to your recent publication!
Ottawa poised to become manufacturing centre for cancer-fighting agent
  Ottawa Citizen 

Funding announcement: BioCanRx gives boost to cell-tracking research
  Schulich School of Medicine & Dentistry

Ottawa researchers to play lead role in new cancer immunotherapy studies
  The Ottawa Hospital Research Institute

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells
  Biotechnology Focus 

Immunotherapy: The next frontier in cancer treatment
  CBS News 

Colorectal Cancer Awareness Month: How Immunotherapy Offers Hope for the Future
  The Cancer Research Institute

Triple-threat viral vaccine cures abdominal cancer in animal models
  The Ottawa Hospital Research Institute

Kite's CAR T-Cell Therapy Success
  The Scientist

Fred Hutch scientists use novel 'barcode' system to find effective cancer-killing T cells

CRISPR turbocharges CAR T cells, boosts cancer immunotherapy

There could be a surprising link between how people respond to a new cancer treatment and their microbiome
  Business Insider 
A message from BioCanRx's President and CEO on International Women's Day.
Copyright © BioCanRx, All rights reserved.

Be a part of the BioCanRx community! Please send news and information to:
Danielle Jones, Officer, Communications and Marketing, BioCanRx

Our mailing address is:
501 Smyth Road, Box 611, Ottawa, Ontario K1H 8L6

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
BioCanRx · 501 Smyth Road, Box 611 · Ottawa, On K1H 8L6 · Canada

Email Marketing Powered by Mailchimp